Cost-Effectiveness Analysis of a Pharmacist-Led Medication Therapy Management Program: Hypertension Management

ObjectivesUncontrolled hypertension is a common cause of cardiovascular disease, which the deadliest and costliest chronic disease in United States. Pharmacists are an accessible community healthcare resource equipped with clinical skills to improve management through medication therapy (MTM). Nevertheless, current reimbursement models do not incentivize pharmacists provide services. We aim investigate cost-effectiveness pharmacist-led comprehensive MTM clinic compared no for 10-year primary prevention stroke events patients hypertension.MethodsWe built semi-Markov model evaluate economic consequences clinic, from payer perspective. The was populated data recently published controlled observational study investigating effectiveness clinic. Methodology guided using recommendations Second Panel on Cost-Effectiveness Health Medicine, including appropriate sensitivity analyses.ResultsCompared cost-effective incremental ratio $38 798 per quality-adjusted life year (QALY) gained. net monetary benefit $993 294 considering willingness-to-pay threshold $100 000 QALY. Health-benefit benchmarks at QALY $150 translate 95% 170% increase rates services.ConclusionsOur shows services may undervalue realized by US payers. New needed allow offer